25 results on '"Saenger, Yvonne"'
Search Results
2. Using tumor growth rate to inform treatment efficacy in pancreatic adenocarcinoma: From the metastatic to the neoadjuvant setting.
3. A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.
4. Cytotoxic t lymphocyte (CTL) to macrophage ratio to predict survival in stage II-III melanoma: Validation in a second cohort.
5. Effect of automated TIL quantification in early-stage melanoma on accuracy of standard T staging using AJCC guidelines.
6. Nivolumab for hepatocellular carcinoma (HCC) in a real-world context.
7. Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.
8. Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.
9. Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.
10. Correlation of immune infiltration of cytotoxic T cells and activated microglia in glioblastoma (GBM) post anti-PD1 therapy with response.
11. Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma.
12. Impact of microsatellite instability status and sidedness of the primary tumor on immunophenotype of colorectal cancer.
13. Effect of combination immunotherapy on tumor growth, survival, and intratumoral immune infiltration in transgenic murine model of melanoma.
14. Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma.
15. Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).
16. Interrogating the sarcoma immune microenvironment (iME) using multiplex immunohistochemistry (mIHC).
17. Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.
18. Characterization of the tumor immune microenvironment (TIM) with multiplex immunohistochemistry (mIHC) in patients with breast cancer following treatment with MK-2206.
19. Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC.
20. In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.
21. Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.
22. Treatment of solid tumors with intratumoral poly-ICLC: A phase II clinical study.
23. Immune gene expression in primary melanomas to predict lower risk of recurrence and death.
24. CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).
25. Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.